Hepatic ImpairmentNo dedicated clinical studies have been conducted to evaluatethe effect of hepatic impairment on the pharmacokinetics of Osimertinib. Based on population pharmacokinetic (PK) analysis, no dose adjustment is recommended in patients withmild hepatic impairment [total bilirubin